{"id":"olopatadine-0-1-rescue-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Taste perversion"}]},"_chembl":{"chemblId":"CHEMBL1189432","moleculeType":"Small molecule","molecularWeight":"337.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olopatadine works through dual action: it competitively antagonizes H1 receptors on ocular tissues to block histamine-induced symptoms, and simultaneously stabilizes mast cells to prevent degranulation and release of inflammatory mediators. This combination provides both rapid symptom relief and sustained anti-allergic effects for ocular allergy management.","oneSentence":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:58.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic conjunctivitis (rescue/acute treatment)"}]},"trialDetails":[{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT00562159","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":439},{"nctId":"NCT00550550","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":345}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pantanol"],"phase":"phase_3","status":"active","brandName":"Olopatadine 0.1% Rescue Treatment","genericName":"Olopatadine 0.1% Rescue Treatment","companyName":"ALK-Abelló A/S","companyId":"alk-abell-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (rescue/acute treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}